| Budget Amount *help |
¥23,920,000 (Direct Cost: ¥18,400,000、Indirect Cost: ¥5,520,000)
Fiscal Year 2017: ¥7,020,000 (Direct Cost: ¥5,400,000、Indirect Cost: ¥1,620,000)
Fiscal Year 2016: ¥7,020,000 (Direct Cost: ¥5,400,000、Indirect Cost: ¥1,620,000)
Fiscal Year 2015: ¥9,880,000 (Direct Cost: ¥7,600,000、Indirect Cost: ¥2,280,000)
|
|---|
| Outline of Final Research Achievements |
Recombinant thrombomodulin (rTM) inhibited histone-induced platelet aggregation and neutrophil extracellular trap (NET) formation in vitro. rTM also inhibited histone-induced NET formation in kidneys, and attenuated histone-induced renal dysfunction in rats. rTM with a chondroitin sulfate side chain (rTM type II) had higher affinity for histone H3 and H4 than the traditional rTM (Type I), and thus, inhibited histone-induced platelet aggregation and NET formation more efficiently than rTM type I. These findings suggest that rTM type II can be a promising therapeutic option for sepsis-associated disseminated intravascular coagulation. Further studies are needed to elucidate in vivo effects of rTM type II in septic conditions.
|
